Zinc oxide nanoparticles antagonize the effect of Cetuximab on head and neck squamous cell carcinoma in vitro

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66:7-30; PMID:28055103; https://doi.org/10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Chan GG, Tai BC, Liang S, Lim DT, Soo KC. Squamous cell carcinoma of the head and neck (HNSCC)–multi-modality treatment and impact on survival. Asian J Surg 2002; 25:35-40; PMID:17585443
   PubMedGoogle Scholar
• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians 2016; 66:271-89; PMID:27253694; https://doi.org/10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301-11; PMID:15837620; https://doi.org/10.1016/j.ccr.2005.03.003
   PubMed Web of Science ®Google Scholar
• Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 1986; 83:3825-9; PMID:2424012; https://doi.org/10.1073/pnas.83.11.3825
   PubMed Web of Science ®Google Scholar
• Kies MS, Holsinger FC, Lee JJ, William WN, Jr., Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28:8-14; PMID:19917840; https://doi.org/10.1200/JCO.2009.23.0425
   PubMed Web of Science ®Google Scholar
• Rampino M, Bacigalupo A, Russi E, Schena M, Lastrucci L, Iotti C, Reali A, Musu A, Balcet V, Piva C, et al. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Res 2012; 32:195-9; PMID:22213307; http://ar.iiarjournals.org/content/32/1/195.long
   PubMed Web of Science ®Google Scholar
• Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, Branstetter BF, Posluszny DM, Wang L, Seethala RR, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 2010; 28:5294-300; PMID:21079141; https://doi.org/10.1200/JCO.2010.30.6423
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-78; PMID:16467544; https://doi.org/10.1056/NEJMoa053422
   PubMed Web of Science ®Google Scholar
• Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23:1287-92; PMID:21948811; https://doi.org/10.1093/annonc/mdr401
   PubMed Web of Science ®Google Scholar
• Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21:2284-9; PMID:20427347; https://doi.org/10.1093/annonc/mdq216
   PubMed Web of Science ®Google Scholar
• Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24:1072-8; PMID:16505426; https://doi.org/10.1200/JCO.2004.00.1792
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27; PMID:18784101; https://doi.org/10.1056/NEJMoa0802656
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology G. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23:8646-54; PMID:16314626; https://doi.org/10.1200/JCO.2005.02.4646
   PubMed Web of Science ®Google Scholar
• Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009; 9:1421-8; PMID:19828002; https://doi.org/10.1586/era.09.113
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007 Jun 1; 25(16):2171-7; PMID:17538161; https://doi.org/10.1200/JCO.2006.06.7447
   PubMed Web of Science ®Google Scholar
• Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113:823-39; PMID:16002369; https://doi.org/10.1289/ehp.7339
   PubMed Web of Science ®Google Scholar
• Colvin VL. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 2003; 21:1166-70; PMID:14520401; https://doi.org/10.1038/nbt875
   PubMed Web of Science ®Google Scholar
• Yeber MC, Rodriguez J, Freer J, Duran N, Mansilla HD. Photocatalytic degradation of cellulose bleaching effluent by supported TiO2 and ZnO. Chemosphere 2000; 41:1193-7; PMID:10901246; https://doi.org/10.1016/S0045-6535(99)00551-2
   PubMed Web of Science ®Google Scholar
• Li D, Haneda H. Morphologies of zinc oxide particles and their effects on photocatalysis. Chemosphere 2003; 51:129-37; PMID:12586145; https://doi.org/10.1016/S0045-6535(02)00787-7
   PubMed Web of Science ®Google Scholar
• Zhang AP, Sun YP. Photocatalytic killing effect of TiO2 nanoparticles on Ls-174-t human colon carcinoma cells. World J Gastroenterol 2004; 10:3191-3; PMID:15457572; https://doi.org/10.3748/wjg.v10.i21.3191
   PubMed Web of Science ®Google Scholar
• Seo JW, Chung H, Kim MY, Lee J, Choi IH, Cheon J. Development of water-soluble single-crystalline TiO2 nanoparticles for photocatalytic cancer-cell treatment. Small 2007; 3:850-3; PMID:17385208; https://doi.org/10.1002/smll.200600488
   PubMed Web of Science ®Google Scholar
• Hackenberg S, Scherzed A, Kessler M, Froelich K, Ginzkey C, Koehler C, Burghartz M, Hagen R, Kleinsasser N. Zinc oxide nanoparticles induce photocatalytic cell death in human head and neck squamous cell carcinoma cell lines in vitro. Int J Oncol 2010; 37:1583-90; PMID:21042728; https://doi.org/10.3892/ijo_00000812
   PubMed Web of Science ®Google Scholar
• Hackenberg S, Scherzed A, Gohla A, Technau A, Froelich K, Ginzkey C, Koehler C, Burghartz M, Hagen R, Kleinsasser N. Nanoparticle-induced photocatalytic head and neck squamous cell carcinoma cell death is associated with autophagy. Nanomedicine (Lond) 2014; 9:21-33; PMID:23731458; https://doi.org/10.2217/nnm.13.41
   PubMed Web of Science ®Google Scholar
• Hackenberg S, Scherzed A, Harnisch W, Froelich K, Ginzkey C, Koehler C, Hagen R, Kleinsasser N. Antitumor activity of photo-stimulated zinc oxide nanoparticles combined with paclitaxel or cisplatin in HNSCC cell lines. J Photochem Photobiol B, Biol 2012; 114:87-93; PMID:22722055; https://doi.org/10.1016/j.jphotobiol.2012.05.014
   PubMed Web of Science ®Google Scholar
• Rasmussen JW, Martinez E, Louka P, Wingett DG. Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. Expert Opin Drug Deliv 2010; 7:1063-77; PMID:20716019; https://doi.org/10.1517/17425247.2010.502560
   PubMed Web of Science ®Google Scholar
• Mo R, Jiang T, Gu Z. Recent progress in multidrug delivery to cancer cells by liposomes. Nanomedicine (Lond) 2014; 9:1117-20; PMID:25118703; https://doi.org/10.2217/nnm.14.62
   PubMed Web of Science ®Google Scholar
• Hanley C, Layne J, Punnoose A, Reddy KM, Coombs I, Coombs A, Feris K, Wingett D. Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles. Nanotechnology 2008; 19:295103; PMID:18836572; https://doi.org/10.1088/0957-4484/19/29/295103
   PubMed Web of Science ®Google Scholar
• Yin H, Casey PS, McCall MJ, Fenech M. Size-dependent cytotoxicity and genotoxicity of ZnO particles to human lymphoblastoid (WIL2-NS) cells. Environ Mol Mutagen 2015; 56:767-76; PMID:26248212; https://doi.org/10.1002/em.21962
   PubMed Web of Science ®Google Scholar
• Chandrasekaran M, Pandurangan M. In Vitro Selective Anti-Proliferative Effect of Zinc Oxide Nanoparticles Against Co-Cultured C2C12 Myoblastoma Cancer and 3T3-L1 Normal Cells. Biol Trace Elem Res 2016; 172:148-54; PMID:26563419; https://doi.org/10.1007/s12011-015-0562-6
   PubMed Web of Science ®Google Scholar
• Brun NR, Lenz M, Wehrli B, Fent K. Comparative effects of zinc oxide nanoparticles and dissolved zinc on zebrafish embryos and eleuthero-embryos: importance of zinc ions. Sci Total Environ 2014; 476–477:657-66; PMID:24508854; https://doi.org/10.1016/j.scitotenv.2014.01.053
   PubMed Web of Science ®Google Scholar
• Xia T, Kovochich M, Liong M, Madler L, Gilbert B, Shi H, Yeh JI, Zink JI, Nel AE. Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. ACS Nano 2008; 2:2121-34; PMID:19206459; https://doi.org/10.1021/nn800511k
   PubMed Web of Science ®Google Scholar
• Nagajyothi PC, Cha SJ, Yang IJ, Sreekanth TV, Kim KJ, Shin HM. Antioxidant and anti-inflammatory activities of zinc oxide nanoparticles synthesized using Polygala tenuifolia root extract. J Photochem Photobiol B 2015; 146:10-7; PMID:25777265; https://doi.org/10.1016/j.jphotobiol.2015.02.008
   PubMed Web of Science ®Google Scholar
• Wang C, Hu X, Gao Y, Ji Y. ZnO Nanoparticles Treatment Induces Apoptosis by Increasing Intracellular ROS Levels in LTEP-a-2 Cells. Biomed Res Int 2015; 2015:423287; PMID:26339612; https://doi.org/10.1155/2015/423287
   PubMed Web of Science ®Google Scholar
• Vandebriel RJ, De Jong WH. A review of mammalian toxicity of ZnO nanoparticles. Nanotechnol Sci Appl 2012; 5:61-71; PMID:24198497; https://doi.org/10.2147/NSA.S23932
   PubMedGoogle Scholar
• Guo D, Wu C, Jiang H, Li Q, Wang X, Chen B. Synergistic cytotoxic effect of different sized ZnO nanoparticles and daunorubicin against leukemia cancer cells under UV irradiation. J Photochem Photobiol B 2008; 93:119-26; PMID:18774727; https://doi.org/10.1016/j.jphotobiol.2008.07.009
   PubMed Web of Science ®Google Scholar
• Hadjipanayis CG, Machaidze R, Kaluzova M, Wang L, Schuette AJ, Chen H, Wu X, Mao H. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010; 70:6303-12; PMID:20647323; https://doi.org/10.1158/0008-5472.CAN-10-1022
   PubMed Web of Science ®Google Scholar
• Karmani L, Labar D, Valembois V, Bouchat V, Nagaswaran PG, Bol A, Gillart J, Levêque P, Bouzin C, Bonifazi D, et al. Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol Imaging 2013; 8:402-8; PMID:23740810; https://doi.org/10.1002/cmmi.1539
   PubMed Web of Science ®Google Scholar
• Tseng SH, Chou MY, Chu IM. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. Int J Nanomedicine 2015; 10:3663-85; PMID:26056447; https://doi.org/10.2147/IJN.S80134
   PubMed Web of Science ®Google Scholar
• Deng ZJ, Mortimer G, Schiller T, Musumeci A, Martin D, Minchin RF. Differential plasma protein binding to metal oxide nanoparticles. Nanotechnology 2009; 20:455101; PMID:19822937; https://doi.org/10.1088/0957-4484/20/45/455101
   PubMed Web of Science ®Google Scholar
• Roy R, Das M, Dwivedi PD. Toxicological mode of action of ZnO nanoparticles: Impact on immune cells. Mol Immunol 2015; 63:184-92; PMID:25193324; https://doi.org/10.1016/j.molimm.2014.08.001
   PubMed Web of Science ®Google Scholar
• Zenner HP, Lehner W, Herrmann IF. Establishment of carcinoma cell lines from larynx and submandibular gland. Arch Otorhinolaryngol 1979; 225:269-77; PMID:548013; https://doi.org/10.1007/BF00455679
   PubMedGoogle Scholar
• Rangan SR. A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 1972; 29:117-21; PMID:4332311; https://doi.org/10.1002/1097-0142(197201)29:1<117::AID-CNCR2820290119>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; https://doi.org/10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar